Autres langues China Medical System Holdings Limited

Actions

867 KYG211081248

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:09:09 25/04/2024			Varia. 5j.	Varia. 1 janv.
7,07 ^HKD	+0,57 %		+0,14 %	-48,92 %

23/04	China Medical System Holdings Limited annonce que la demande d'autorisation de mise sur le marché du Desidustat Tablets a été acceptée en Chine	CI
02/04	China Medical System Holdings Limited (SEHK:867) commence un rachat d'actions pour 245 198 851 actions, représentant 10% de son capital social émis, dans le cadre de l'autorisation approuvée le 28 avril 2023.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

China Medical System: New Drug Application of Desidustat Tablets Accepted in China	23/04
China Medical System's Anti-Anaemia NDA Accepted in China	23/04
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China	23/04
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	23/04
China Medical System Registers New Vitiligo Drug in Macau	17/04
China Medical System Holdings Limited commences an Equity Buyback for 245,198,851 shares, representing 10% of its issued share capital, under the authorization approved on April 28, 2023.	02/04
Incyte, China Medical System Sign Collaboration, License Agreement	01/04
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia	01/04
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	01/04
China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs	28/03
China Medical System Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024	27/03
China Medical System's Atopic Dermatitis Cream Gets Regulatory Nod for Phase 3 Trial	20/03
China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China	19/03
China Medical System Obtains Nod For Trials of Two Drugs	08/02
China Medical System Holdings Limited Announces CMS-D001 Tablets and CMS-D002 Capsules Self-Developed	07/02
China Medical Gains License to Sell Kidney Disease Drug Across China	05/02
China Medical System (00867） Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro®	04/02
CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA	02/01
China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL	13/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues China Medical System Holdings Limited

Actions

867

KYG211081248

Autres langues

Filtres